Overview of fenofibrate
- PMID: 9519345
Overview of fenofibrate
Abstract
Fenofibrate is a broad spectrum lipid-lowering agent able to produce substantial reductions in plasma triglyceride and low density lipoprotein (LDL) and an increase in high density lipoprotein (HDL). It acts to promote the clearance of chylomicrons and very low density lipoproteins and can correct abnormalities in the LDL subfraction profile with a shift away from small, dense LDL. The drug is of particular use in correcting the atherogenic lipoprotein phenotype seen commonly in subjects with coronary heart disease. Recent investigations have revealed its likely mechanism of action at the molecular level. Fenofibrate binds to peroxisome proliferator activated receptor and initiates a sequence of events that leads to the reduction of apolipoprotein C-III synthesis in liver. This lipoprotein apoprotein inhibits the lipolysis and uptake of triglyceride-rich particles and suppression of its production causes enhanced catabolism. Further effects such as the changes in LDL and HDL follow from this primary action.
Similar articles
-
Atherogenic, dense low-density lipoproteins. Pathophysiology and new therapeutic approaches.Eur Heart J. 1998 Feb;19 Suppl A:A24-30. Eur Heart J. 1998. PMID: 9519339 Review.
-
Qualitative effect of fenofibrate and quantitative effect of atorvastatin on LDL profile in combined hyperlipidemia with dense LDL.Exp Clin Endocrinol Diabetes. 2004 May;112(5):241-7. doi: 10.1055/s-2004-817970. Exp Clin Endocrinol Diabetes. 2004. PMID: 15146369 Clinical Trial.
-
Differential effect of hypolipidemic drugs on lipoprotein-associated phospholipase A2.Arterioscler Thromb Vasc Biol. 2007 Oct;27(10):2236-43. doi: 10.1161/ATVBAHA.107.147280. Epub 2007 Jul 26. Arterioscler Thromb Vasc Biol. 2007. PMID: 17656665 Clinical Trial.
-
Pharmacologic treatment of type 2 diabetic dyslipidemia.Pharmacotherapy. 2004 Dec;24(12):1692-713. doi: 10.1592/phco.24.17.1692.52340. Pharmacotherapy. 2004. PMID: 15585439 Review.
-
Effectiveness of a fenofibrate 145-mg nanoparticle tablet formulation compared with the standard 160-mg tablet in patients with coronary heart disease and dyslipidemia.Pharmacotherapy. 2008 May;28(5):570-5. doi: 10.1592/phco.28.5.570. Pharmacotherapy. 2008. PMID: 18447655
Cited by
-
Causes and Consequences of Hypertriglyceridemia.Front Endocrinol (Lausanne). 2020 May 14;11:252. doi: 10.3389/fendo.2020.00252. eCollection 2020. Front Endocrinol (Lausanne). 2020. PMID: 32477261 Free PMC article. Review.
-
Association Between Use of Antihyperlipidemic Agents and Chronic Obstructive Pulmonary Disease in Patients with Hyperlipidemia: A Population-Based Retrospective Cohort Study.Int J Chron Obstruct Pulmon Dis. 2020 Oct 20;15:2573-2581. doi: 10.2147/COPD.S267017. eCollection 2020. Int J Chron Obstruct Pulmon Dis. 2020. PMID: 33116474 Free PMC article.
-
PPARα Ameliorates Doxorubicin-Induced Cardiotoxicity by Reducing Mitochondria-Dependent Apoptosis via Regulating MEOX1.Front Pharmacol. 2020 Oct 8;11:528267. doi: 10.3389/fphar.2020.528267. eCollection 2020. Front Pharmacol. 2020. PMID: 33132907 Free PMC article.
-
Ethanol extract of fructus schisandrae decreases hepatic triglyceride level in mice fed with a high fat/cholesterol diet, with attention to acute toxicity.Evid Based Complement Alternat Med. 2011;2011:729412. doi: 10.1093/ecam/nep070. Epub 2011 Jan 4. Evid Based Complement Alternat Med. 2011. PMID: 19592476 Free PMC article.
-
Drug repurposing by in silico prediction of cyclizine derivatives as antihyperlipemic agents.In Silico Pharmacol. 2023 Oct 25;11(1):27. doi: 10.1007/s40203-023-00164-2. eCollection 2023. In Silico Pharmacol. 2023. PMID: 37899967 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical